The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity
Open accessAbstract
Mdm2, a key negative regulator of the p53 tumor suppressor, is a RING-type E3 ubiquitin ligase. The Mdm2 RING domain can be biochemically fractionated into two discrete species, one of which exists as higher order oligomers that are visible by electron microscopy, whereas the other is a monomer. Both fractions are ATP binding and E3 ligase activity competent, although the oligomeric fraction exhibits lower dependence on the E2 component of ubiquitin polymerization reactions. The extreme C-terminal five amino acids of Mdm2 are essential for E3 ligase activity in vivo and in vitro, as well as for oligomeric assembly of the protein. A single residue (phenylalanine 490) in that sequence is critical for both properties. Interestingly, the C-terminus of the Mdm2 homologue, MdmX (itself inert as an E3 ligase), can fully substitute for the equivalent segment of Mdm2 and restore its E3 activity. We further show that the Mdm2 C-terminus is involved in intramolecular interactions and can set up a platform for direct protein-protein interactions with the E2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Work from both the Vousden and Prives laboratories indicatesthat oligomeric Mdm2is a more effectivep53 ubiquitin ligase than is monomeric Mdm2 [27,28].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [28]
In the citing paper
“Intriguingly, their data show that aromatic residues (Y489 and F490) outside the RING domain at the extreme C-terminus are also critical for Mdm2 ligase activity.”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [28]
In the citing paper
“Aromatic residues are conserved in the Mdmx C-terminal tail, and can also act in trans to reactivate E3 ligase function in Mdm2 C-terminal mutants [27,28].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [28]
In the citing paper
“Oligomerization of MDM2 RING domain increases its E3 ligase activity in vitro (Poyurovsky et al, 2007).”
From ATM activates p53 by regulating MDM2 oligomerization and E3 processivity (2009) · cites this paper as Poyurovsky et al, 2007
In the citing paper
“Formation of high-order oligomers is a common feature of RING domains (Kentsis et al, 2002;Poyurovsky et al, 2007).”
From ATM activates p53 by regulating MDM2 oligomerization and E3 processivity (2009) · cites this paper as Poyurovsky et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…Harris and Levine, 2005; Poyurovsky and Prives, 2006), Mdm2 controls p53 through two distinct mechanisms, by directly binding and masking the N-terminal transactivation domain of p53 (Momand et al, 1992) and by promoting proteasomal degradation of p53 (Haupt et al, 1997; Kubbutat et al, 1997).”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Enzyme structure and mechanism
Fersht, A. (1977) · Medical Entomology and Zoology · Cited by 2,875
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Self-citationThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) · Nature · doi:10.1038/416703a · Cited by 1,507
Self-citationMdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Melnick, A. M., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,029
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 203
Regulation of E3 ubiquitin ligases by homotypic and heterotypic assembly
Balaji, V., & Hoppe, T. (2020) · F1000Research · doi:10.12688/f1000research.21253.1 · Cited by 32
Kulkarni, D. A., Vázquez, A., Haffty, B. G., Bandera, E. V., Hu, W., Sun, Y., Toppmeyer, D., Levine, A. J., & Hirshfield, K. M. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp224 · Cited by 33
Borden, K. L. B. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.06.005 · Cited by 34
c-Abl Phosphorylation of Mdm2 Facilitates Mdm2-Mdmx Complex Formation
Waning, D. L., Lehman, J. A., Batuello, C. N., & Mayo, L. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.183012 · Cited by 30
Mdm2 enhances ligase activity of parkin and facilitates mitophagy
Kook, S., Zhan, X., Thibeault, K. C., Ahmed, M. R., Gurevich, V. V., & Gurevich, E. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-61796-4 · Cited by 32
Mdm2 links genotoxic stress and metabolism to p53
Wang, Z., & Li, B. (2010) · Protein & Cell · doi:10.1007/s13238-010-0140-9 · Cited by 30
Turning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase*
Iyappan, S., Wollscheid, H.-P., Rojas‐Fernández, A., Marquardt, A., Tang, H., Singh, R. K., & Scheffner, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.115113 · Cited by 29
Woodsmith, J., Jenn, R. C., & Sanderson, C. M. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.016162 · Cited by 30
Kalousek, I., Brodská, B., Otevřelová, P., & Röselová, P. (2007) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3280adc905 · Cited by 26
Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival
Liu, T., Zhang, H., Xiong, J., Yi, S., Gu, L., & Zhou, M. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0334-0 · Cited by 26
Lee, J.-H., Jin, Y., He, G., Zeng, S. X., Wang, Y. V., Wahl, G. M., & Lu, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.336875 · Cited by 25
Jung, J. H., Lee, H., Zeng, S. X., & Lu, H. (2020) · Cells · doi:10.3390/cells9092107 · Cited by 27
Chopra, H., Khan, Z. A., Contreras, J., Wang, H., Sedrak, A., & Zhu, Y. Y. (2017) · Oncotarget · doi:10.18632/oncotarget.23569 · Cited by 25
Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells
Ray, D., Ray, P., Ferrer-Torres, D., Wang, Z., Nancarrow, D. J., Yoon, H., Martinho, M. S., Hinton, T., Owens, S. R., Thomas, D. G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.10.040 · Cited by 25
Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells
Wade, M. R., Li, Y. C., Matani, A. S., Braun, S. M. G., Milanesi, F., Rodewald, L. W., & Wahl, G. M. (2012) · Oncogene · doi:10.1038/onc.2011.625 · Cited by 25
Oligomeric Structure of the MALT1 Tandem Ig-Like Domains
Qiu, L., & Dhe‐Paganon, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023220 · Cited by 24
Nanosensing protein allostery using a bivalent mouse double minute two (MDM2) assay
Robson, A. F., Hupp, T. R., Lickiss, F., Ball, K. L., Faulds, K., & Graham, D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116637109 · Cited by 24
Protein–protein interactions regulate Ubl conjugation
Knipscheer, P., & Sixma, T. K. (2007) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2007.09.001 · Cited by 25
Peli1 Modulates the Subcellular Localization and Activity of Mdmx
Li, D., Tavana, O., Sun, S., & Gu, W. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3531 · Cited by 22
Lorès, P., Visvikis, O., Luna, R., Lemichez, E., & Gâcon, G. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07575.x · Cited by 23
Perspectives in PML: a unifying framework for PML function
Borden, K. L. B. (2009) · Frontiers in bioscience · doi:10.2741/3258 · Cited by 24
Habu, T., & Harada, K. H. (2021) · FASEB BioAdvances · doi:10.1096/fba.2019-00092 · Cited by 23
Gray, T. A., Murray, E., Nowicki, M. W., Remnant, L., Scherl, A., Müller, P., Vojtesek, B., & Hupp, T. R. (2013) · Protein Science · doi:10.1002/pro.2299 · Cited by 22
Parkin, A Top Level Manager in the Cells Sanitation Department
Rankin, C. A., Roy, A., Zhang, Y., & Richter, M. L. (2011) · The Open Biochemistry Journal · doi:10.2174/1874091x01105010009 · Cited by 21
5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2
Dickens, M. P., Roxburgh, P., Hock, A., Mezna, M., Kellam, B., Vousden, K. H., & Fischer, P. M. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.038 · Cited by 21
Mouse modelling of the MDM2/MDMX−p53 signalling axis
Tackmann, N. R., & Zhang, Y. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx006 · Cited by 21
Gong, M., Li, Z., Wan, J., Chen, M., Wang, H., Shang, J., Zhou, S., Tan, Q., Wang, Y., & Bao, D. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103668 · Cited by 20
Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer
Singh, A. K., Chauhan, S. S., Singh, S. K., Verma, V. V., Singh, A., Arya, R. K., Maheshwari, S., Akhtar, M. S., Sarkar, J., Rangnekar, V. M., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw088 · Cited by 21
MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.
Wu, J., Lu, G., & Wang, X. (2021) · PubMed Central · Cited by 19
PIG3 Regulates p53 Stability by Suppressing Its MDM2-Mediated Ubiquitination
Jin, M., Park, S., Kim, S. W., Kim, H., Hyun, J. W., & Lee, J.-H. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2017.086 · Cited by 17
Tau protein binds to the P53 E3 ubiquitin ligase MDM2
Sola, M., Rendon-Angel, A., Martinez, V. R., Sgrignani, J., Magrin, C., Piovesana, E., Cavalli, A., Paganetti, P., & Papin, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-37046-8 · Cited by 17
MDM2 oligomers: antagonizers of the guardian of the genome
Leslie, P. L., & Zhang, Y. (2016) · Oncogene · doi:10.1038/onc.2016.88 · Cited by 18
Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects
Kon, N., Wang, D., Li, T., Jiang, L., Qiang, L., & Gu, W. (2018) · Oncotarget · doi:10.18632/oncotarget.23837 · Cited by 17
Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)
Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16
Deconstructing nucleotide binding activity of the Mdm2 RING domain
Priest, C., Prives, C. L., & Poyurovsky, M. V. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq669 · Cited by 16
Kosztyu, P., Slaninová, I., Valčíková, B., Verlande, A., Müller, P., Palecek, J. J., & Uldrijan, S. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00390 · Cited by 15
Fan, C., & Wang, X. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1288327 · Cited by 16
Yao, S., Xie, M., Hu, M., Cui, X., Wu, H., Li, X., Hu, P., Tong, C., & Yu, X. (2023) · Frontiers in Plant Science · doi:10.3389/fpls.2023.1118339 · Cited by 15
Luo, X., Zhang, L., Han, G.-D., Lu, P., & Zhang, Y. (2020) · Human & Experimental Toxicology · doi:10.1177/0960327120952158 · Cited by 15
NMR assignment of the arenaviral protein Z from Lassa fever virus
Volpon, L., Osborne, M. J., & Borden, K. L. B. (2008) · Biomolecular NMR Assignments · doi:10.1007/s12104-008-9090-z · Cited by 14
The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis
Hu, H., Zhao, K., Fang, D., Wang, Z., Yu, N., Yao, B., Liu, K., Wang, F., & Mei, Y. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112288 · Cited by 13
Cheng, W.-Y., Chen, J., Liang, Z.-Q., Li, G., Yi, C., Wang, W., & Wang, K.-Y. (2012) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2012.01.010 · Cited by 13
Caging the Beast: TRIM5α Binding to the HIV-1 Core
Diaz‐Griffero, F. (2011) · Viruses · doi:10.3390/v3050423 · Cited by 13
Protein grafting of p53TAD onto a leucine zipper scaffold generates a potent HDM dual inhibitor
Lee, J., Kang, E., Lee, J., Kim, J., Lee, K. H., Han, J., Kang, H. Y., Ahn, S.-S., Oh, Y., Shin, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms4814 · Cited by 13
Differential requirements for MDM2 E3 activity during embryogenesis and in adult micePreprint
Humpton, T. J., Nomura, K., Weber, J., Magnussen, H., Hock, A. K., Nixon, C., Dhayade, S., Stevenson, D., Huang, D. T. C., Strathdee, D., et al. (2020) · Genes & Development · doi:10.1101/gad.341875.120 · Cited by 11
A site-directed mutagenesis study of the MdmX RING domain
Egorova, O., & Sheng, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.065 · Cited by 10
Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice
Tian, H., Tackmann, N. R., Jin, A., Zheng, J., & Zhang, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000122 · Cited by 9
p53 Regulation Goes Live--Mdm2 and MdmX Co-Star: Lessons Learned from Mouse Modeling
Tollini, L. A., & Zhang, Y. (2012) · Genes & Cancer · doi:10.1177/1947601912454732 · Cited by 9
Mutational analysis reveals a dual role of Mdm2 acidic domain in the regulation of p53 stability
Doleželová, P., Cetkovská, K., Vousden, K. H., & Uldrijan, S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.05.034 · Cited by 9
Bioinformatics advances in protein ubiquitination
Liang, L. U., Li, D., & He, F. (2013) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2013.00017 · Cited by 10
Johnson, A. E., Collier, S. E., Ohi, M. D., & Gould, K. L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.349712 · Cited by 9
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 7
Sanford, J. D., Yang, J., Han, J., Tollini, L. A., Jin, A., & Zhang, Y. (2021) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00385-3 · Cited by 7
Márquez-Cantudo, L., Ramos, A., Coderch, C., & de Pascual‐Teresa, B. (2021) · Molecules · doi:10.3390/molecules26185606 · Cited by 8
Alterations of the Mdm2 C-Terminus Differentially Impact Its Function In Vivo
Pant, V., Aryal, N. K., Xiong, S., Chau, G. P., Fowlkes, N. W., & Lozano, G. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2381 · Cited by 6
Tang, Y., Tang, Z., Zhang, Y., Zhuo, M., Zang, G., Chen, X., & Yu, Y. (2014) · Hepatitis Monthly · doi:10.5812/hepatmon.16161 · Cited by 6
Hauck, P. M., Wolf, E. R., Olivos, D. J., McAtarsney, C. P., & Mayo, L. D. (2017) · Oncotarget · doi:10.18632/oncotarget.22320 · Cited by 6
UHRF1P contributes to IL-17A-mediated systemic lupus erythematosus via UHRF1-MAP4K3 axis
Chuang, H., Lan, K.-Y., Hsu, P., Chen, M., Chen, Y., Yen, J., Liao, B., & Tan, T. (2024) · Journal of Autoimmunity · doi:10.1016/j.jaut.2024.103221 · Cited by 5
Intra molecular interactions in the regulation of p53 pathway
Chen, J. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.09.23 · Cited by 5
MDMX under stress: the MDMX-MDM2 complex as stress signals hub
de Polo, A., Vivekanandan, V., Little, J. B., & Yuan, Z.-M. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.12.18 · Cited by 4
Attili, M., Valentini, S., Pesavento, M., Ballarotto, M., Scognamiglio, V., Pontecorvi, A., Macchiarulo, A., Saccoccia, F., & Moretti, F. (2025) · Frontiers in Chemical Biology · doi:10.3389/fchbi.2025.1576640 · Cited by 3
Mathematical Modeling of Linear Docking. I. Determination of Regions of Binding of Protein Molecules
Kulikov, K. G., & Koshlan, T. (2018) · Technical Physics · doi:10.1134/s1063784218080108 · Cited by 3
Yin, Q., Hu, Y., Dong, Z., Lu, J., & Wang, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00913 · Cited by 3
Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant
Magnussen, H., & Huang, D. T. C. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166807 · Cited by 3
Millado, J. B. H., Hamajima, R., Sugiura, W., Makino, S., Kobayashi, M., & Ikeda, M. (2021) · Journal of insect biotechnology and sericology · doi:10.11416/jibs.90.2_021 · Cited by 3
Fuentes, M., Srivastava, S., Gronenborn, A. M., & LaBaer, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010053 · Cited by 3
Cooperation between MDM2 and MDMX in the Regulation of p53
Blaydes, J. P. (2010) · Molecular biology intelligence unit · doi:10.1007/978-1-4419-8231-5_6 · Cited by 2
Lien, S. (2024) · American Journal of Cancer Research · doi:10.62347/qifc4021 · Cited by 1
Wang, C., Liu, W.-T., Guo, H., Lan, T., Wang, T., & Wang, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115286 · Cited by 1
Mathematical Modeling Identification of Active Sites Interaction of Protein Molecules
Koshlan, T., & Kulikov, K. G. (2018) · Biological and medical physics, biomedical engineering · doi:10.1007/978-3-319-98304-2_5 · Cited by 1
Zou, X., Yu, H., & Li, Q. (2023) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2023.101108 · Cited by 1
Sun, R., Zhou, Y., Liang, J., Yang, L., Fan, Z.-J., & Wang, H. (2023) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2023.152183 · Cited by 1
FBXO46 negatively regulates p53 activity by stabilizing Mdm2
Wei, L., Yu, N., Yao, B., Mei, Y., & Zhao, K. (2024) · FEBS Letters · doi:10.1002/1873-3468.15055 · Cited by 1
CHK2 is Negatively Regulated by Protein Phosphatase 2A
Freeman, A. K. (2010) · Digital Commons - University of South Florida (University of South Florida)
Multiple modes of Mdmx regulation affect p53 activation
Gilkes, D. M. (2008) · Digital Commons - University of South Florida (University of South Florida)
Sarek, G. (2010) · Työväentutkimus Vuosikirja
Selectivity of E2-E3 interactions in the human ubiquitin system
van Wijk, S. J. L. (2010) · Utrecht University Repository (Utrecht University)
TARGETING THE MDM2-P53 AXIS FOR THE TREATMENT OF DEDIFFERENTIATED LIPOSARCOMA
Bill, K. (2014) · Digital Commons-TMC (Texas Medical Center)
Small molecule inhibitors of Mdm2 E3 ubiquitin ligase activity
Dickens, M. P. (2011) · UPT. Syiah Kuala University Library (Syiah Kuala University)
Increased Radioresistance and Accelerated B Cell LymphomasinMicewithMdmxMutationsthatPrevent
Wang, Y. V., Leblanc, M., Wade, M. R., Jochemsen, A. G., & Wahl, G. M. (2009)
Progress in regulation of activity and stability of ubiquitin protein ligase MDM2
Nie, J., Tian, C., & Zhang, L. (2009) · Hereditas (Beijing) · doi:10.3724/sp.j.1005.2009.00993
Structural and functional characterization of the p53 C- terminus
Kim, S. K. (2012) · eScholarship (California Digital Library)
Proteasomal Degradation of Soluble, Misfolded Proteins
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800186-8.00003-1
Rosso, M. (2015) · CUNY Academic Works (City University of New York)
Structural and Functional Characterization of the Human Mdm2 and MdmX RING Domains
Egorova, O. (2014) · YorkSpace (York University)
Oliveira, D. V. C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2019.tde-18022019-101454
Monteiro, L. F. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.87.2019.tde-11042019-135708
Data from RING Domain–Mediated Interaction Is a Requirement for MDM2's E3 Ligase Activity
Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D., & Yuan, Z.-M. (2023) · doi:10.1158/0008-5472.c.6495950
Data from RING Domain–Mediated Interaction Is a Requirement for MDM2's E3 Ligase Activity
Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D., & Yuan, Z.-M. (2023) · doi:10.1158/0008-5472.c.6495950.v1
Data from A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2023) · doi:10.1158/1535-7163.c.6531407
Data from A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2023) · doi:10.1158/1535-7163.c.6531407.v1
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C. L., & Stockwell, B. R. (2023) · doi:10.1158/2159-8290.22529165.v1
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C. L., & Stockwell, B. R. (2023) · doi:10.1158/2159-8290.22529165
Novel concepts in MDM2 protein regulation
Worrall, E. G. (2009) · ERA
Sanford, J. D., Yang, J., Han, J., Tollini, L. A., Jin, A., & Zhang, Y. (2021) · Figshare · doi:10.6084/m9.figshare.16664347
Malhab, L. J. B. (2016) · theses.fr (ABES) · doi:10.70675/a9a79207z0857z4ed5zb207z749cdceb9430
Implication de la voie p53 dans les syndromes d'insuffisance médullaire
Durand, R. (2020) · theses.fr (ABES) · doi:10.70675/6ccc120bz65f7z4c6czabf5z9bea26651b66
Adewumi, A. T., Sekele, L., Oluyemi, W. M., Eze, S. C., & Mosebi, S. (2026) · Biomedicines · doi:10.3390/biomedicines14102366
Metadata
- Authors
- Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z., Pavletich, N., & Prives, C.
- Affiliations
- Columbia University (US)
- New York University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Prives, Carol
- ORCID
- Venue
- The EMBO Journal
- Published
- 2006-12-14
- Volume
- 26
- Issue
- 1
- Pages
- 90-101
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC1782380
- OpenAlex
- W2123242499
- Cited by
- 203
- References
- 46
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 12 · 2022: 3 · 2021: 11 · 2020: 14 · 2019: 6 · 2018: 6 · 2017: 9 · 2016: 10 · 2015: 7 · 2014: 9 · 2013: 10 · 2012: 18
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The EMBO Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA58316, CA87497)
- National Cancer Institute (R37CA058316, CA-87497, P01CA087497, R01CA058316, CA 58316)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- MDM2, RING domain, E3 ubiquitin ligase, protein oligomerization, supramolecular self-assembly, C-terminal domain, p53 regulation, MDMX, E2 ubiquitin-conjugating enzyme, intramolecular interactions, protein-protein interaction, ubiquitination
- MeSH terms
- Adenosine Triphosphate, Escherichia coli, Humans, Microscopy, Electron, Models, Biological, Nuclear Proteins, Phenylalanine, Protein Binding, Protein Conformation, Tumor Suppressor Protein p53, Protein Structure, Tertiary, Ubiquitin, Ubiquitin-Protein Ligases, Cell Line, Tumor, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review